BioPharma Services: Advanced Genomic Solutions
Finding Answers Starts with the Right Diagnostic Partner
Behind every effective drug therapy is a patient who once had only hope and now has an answer. Life-changing answers. Our mission is to design each test as though we were developing it for one of our own family members. For us it’s personal.
Experience Matters
For the last 20 years, Ambry has been seeking to better understanding gene-disease relationships through collaboration, research and innovation. We have identified novel genes, designed custom assays, and brought to market more than 500 unique diagnostic tests. We’ve been first-to-market with game-changing technologies, including clinical exome and hereditary cancer panels. As a committed team of experts, we are equipped with powerful technologies and stand by ready to develop custom assays to meet your specific criteria, as if it were family.
Pioneers of Next Generation Sequencing
Ambry scientists have been working with NGS platforms since 2007. In 2008, Ambry became the 3rd Illumina CSPro sequencing provider in the world and began offering contract research services. We were among the first to perform whole exome sequencing, create custom gene panels using custom probe design and obtain CSPro status from Roche-Nimble and Agilent. We are seasoned experts that can take your project from concept to completion.
Ambry’s CLIA-approved CAP-certified, New York approved lab boasts more than 65,000 sq. feet of highly-automated equipment, optimized for everything from large scale, volume testing to customized research projects. Our comprehensive end-to-end Precision Medicine workflow includes the following platforms:
- Illlumina Sequencing
- Affymetrix CytoScan, OncoScan and Gene Expression
- Agilent Arrays
- Probe-based Target Enrichment from IDT, Agilent and Roche
- ArcherDX FusionPlex and Immunoverse
Ambry has a department of professionals dedicated to managing and administering key elements of our Quality Management System (QMS). We maintain our Service Organization Control (SOC2) Certification through the implementation of strict guidelines for:
- Licensure & credentialing
- Disaster recovery
- Proficiency testing
- Sample chain of custody
- Adventitious Virus Detection
- ctDNA Analysis
- Immuno-oncology Biomarker Analysis
- Pathology/Histology
Drug development and companion diagnostics require a quality lab partner. From disease diagnosis to drug discovery to companion diagnostic development, our advanced technologies deliver a more efficient solution to expedite new drug discovery and development.
Our extensive NGS capabilities include exome, whole transcriptome and targeted sequencing, tumor profiling, targeted ctDNA analysis, array-based copy number and gene expression technologies, immuno-oncology assays (B= and T-cell repertoire and tumor microenvironment), custom assay development – all delivered with our comprehensive high-quality reporting.
- Sequencing Platforms: Illumina Hiseq2500, Hiseq4000, Nextseq and Miseq
- Germline disease panels
- Whole Genome and Exome Sequencing
- SNP Genotyping
- Quantitative PCR (qPCR)
- Mitochondria Analysis
- Tumor Profiling DNA Panels
- TumorNext-142: Targeted somatic/germline panel for FDA-approved and investigational therapies
- TumorNext-MMR-HRD: Targeted simultaneous somatic/germline panel for targeted treatment for mismatch repair and homologous recombination deficiency
Ambry, a leading genetic test provider is now coupled with Invicro offering quantitative biomarker research, under the Konica Minolta Precision Medicine umbrella. Together we offer a full suite of services for pharma development as a single-source provider, including:
- Genetic testing
- High sensitivity tissue testing
- Full range of image informatics, engineering and operational services
- Strong relationships and solid contracts with payers
- Large field sales organization to supports trial recruitment
- Patient eligibility for rare disease products on the market
- CDx distribution and synergized commercialization/recruitment efforts
Source: Genetic Engineering & Biotech News, Nov 2015
Chief Medical Officer, Advanced Genomic & Pathology Services
Dr. Bloom brings more than 30 years of clinical and business experience in pathology, oncology, telemedicine, and bioinformatics. His role will be to help expand, strengthen and commercialize the full-suite of precision medicine capabilities offered within the pathology and genomics markets for Invicro and Ambry Genetics.
Previously, Dr. Bloom was President and Head of Oncology & Immunotherapy for Human Longevity Inc., where his team developed and commercialized an industry leading cancer exome product and commercialized a technique for validating neoantigens predicted from sequencing. Dr. Bloom was also instrumental to the business strategy that evolved Clarient from a start-up to the acquisition by GE Healthcare.
Prior to his industry experience, Dr. Bloom spent 15 years within the academic field holding various appointed positions including Director of Laboratory Operations and Chief Information Officer of the Rush Cancer Institute, Clinical Professor of Pathology at University of Southern California, Keck School of Medicine; and Associate Professor of Pathology at Rush Medical College. Dr. Bloom received his MD from Rush Medical College and his BA from Grinnell College.
All Ambry tests are developed and validated in full compliance with all federal, state and local laws, rules and regulations; including CLIA, New York State and CAP standards. Our test performance is routinely and closely monitored to ensure the timely delivery of accurate test results to our clients and their patients.
In Partnership With
